NEURACAP
Sector OutlookPublished · 21 pages · Free to read

Therapeutic Discovery Platforms Sector Outlook — September 2026

A sector outlook on Therapeutic Discovery Platforms companies, covering how the public market prices seven clinical-stage platform companies on EV / Revenue (CY2027E), what precedent transactions reveal about buyer behavior, and the capital-allocation questions this pricing raises for platform owners and acquirers.

For information only. Not an appraisal or a fairness opinion.

What moved since: Therapeutic Discovery Platforms M&A update, 14–28 September 2026

Key figures

Sector median valuation
2.7x
EV / Revenue, CY2027E consensus
Top of the forward range
18.3x
Denali Therapeutics Inc. (DNLI), EV / Revenue CY2027E
Bottom of the forward range
0.8x
Cellectis S.A. (CLLS), EV / Revenue CY2027E
Largest disclosed transaction
$6.6B
Johnson & Johnson acquisition of Momenta Pharmaceuticals, Inc.

Read the report

NeuraCap

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS

Therapeutic Discovery Platforms: Priced One by One

How the market is currently pricing platform reusability against single-asset dependency across the clinical-stage platform companies on this screen, and what the transaction record shows about who is buying.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice

1

1 / 21

Executive summary

Seven Therapeutic Discovery Platforms companies share one segment label, but only four carry a rated EV / Revenue (CY2027E) multiple, spanning 18.3x to 0.8x against a 2.7x sector median. Precedent deals since 2019 show strategic buyers paying up to $6.6B for whole platforms, while sponsors have targeted services-oriented assets instead. In our view, the spread is associated with pipeline breadth and revenue quality, not causation from either alone. We'd use this company-level pricing, not the segment label, to frame the next capital-allocation decision.

Key findings

  • Seven platforms share one segment label, but the market prices each on its own terms.
  • Only four of seven companies carry a rated forward multiple, spanning 18.3x to 0.8x.
  • Sector median sits at 2.7x EV/Revenue (CY2027E), the primary valuation lens here.
  • Precedent deals range from a sponsor-led services buy to a $6.6B strategic acquisition.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS

    This cover introduces the Therapeutic Discovery Platforms sector outlook as of September 2026.

    We open this report on Therapeutic Discovery Platforms priced one by one, using EV / Revenue on CY2027E consensus as the primary lens as of September 28, 2026. The pages that follow show why one segment label still produces very different forward prices across the platforms on this screen.

    Everything on this page

    HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › THERAPEUTIC DISCOVERY PLATFORMS Therapeutic Discovery Platforms: Priced One by One How the market is currently pricing platform reusability against single-asset dependency across the clinical-stage platform companies on this screen, and what the transaction record shows about who is buying. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    This slide sets out the report's five sections plus an appendix.

    This report runs five sections plus an appendix: the bottom line, the landscape, valuation and situations, precedent transactions, and strategic implications. We lead with the bottom line by design, so a reader who stops there still leaves with the full argument.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line The Bottom Line on Therapeutic Discovery Platforms 02 The Landscape One Segment Label, Seven Platforms, Four Forward Prices 03 Valuation & Situations Forward Revenue Is the Yardstick This Market Is Read On 04 Precedent Transactions What Buyers Agreed to Pay for Platform Companies 05 Strategic Implications What This Pricing Means for a Platform Owner 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Therapeutic Discovery Platforms Sit in One Segment, and the Market Prices Each Platform Separately

    This slide states that the segment prices each of the seven platforms separately on forward revenue.

    Seven Therapeutic Discovery Platforms companies sit under one segment label, yet only four carry a rated EV / Revenue multiple for CY2027E, with the sector median at 2.7x. Denali Therapeutics Inc. (DNLI) holds the top of that range, and Cellectis S.A. (CLLS) sits at the bottom — a spread the segment label alone doesn't explain. Precedent transactions add another lens: strategic buyers have paid as much as $6.6B for a whole platform, while sponsor buyers have targeted different kinds of assets. Together, these show that the label groups the companies, but the market prices each platform on its own record — so what follows is how to read that record company by company.

    Everything on this page

    01 · THE BOTTOM LINE Therapeutic Discovery Platforms Sit in One Segment, and the Market Prices Each Platform Separately The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (4 of 7 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Forward Revenue Is the Yardstick This Set Is Read On EV / Revenue on CY2027E is the lead convention here: with forward revenue growth in the middle of the range at 45%, a set priced on growth is read on revenue rather than on profit. The middle of the price range sits at 2.7x, and 4 of the 7 companies on the page carry a forward multiple. 2 Platform Breadth Sits Alongside the Top of the Range Denali Therapeutics Inc. (DNLI) holds the top of the range at 18.3x forward revenue, with Cellectis S.A. (CLLS) at the bottom at 0.8x. A forward multiple already credits forecast growth, so a premium that survives it is associated with durability rather than with one year's step-up. 3 Large Pharma Buyers Cluster Around Mechanisms, Sponsor Buyers Around Services Across the 9 transactions in this record, whole-company deals run up to $6.6B, where Johnson & Johnson took Momenta Pharmaceuticals, Inc. At the other end, Arlington Capital Partners took IPA Europe B.V., which reads as a sponsor positioned where cash generation is legible rather than where clinical risk sits. 4 Collaboration Economics Are the Revenue Quality You Control On the 4 companies carrying a forward growth estimate, the readings are far apart: Cellectis S.A. (CLLS) at 72% and Bicycle Therapeutics plc (BCYC) at -52%. Upfronts, option-to-license terms and the milestone and royalty stack are where revenue quality is shaped between clinical readouts. 2.7x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because only 1 of 7 names carry a meaningful forward EBITDA 18.3x Premium end EV/Revenue vs 0.8x at the discount end top quartile (n=1) against bottom quartile (n=1) on EV/Revenue — the spread the report explains 12 Transactions with disclosed terms 45 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    This divider introduces the market-map section covering the seven companies in one segment.

    We turn now to the landscape: one segment label, seven platform companies, and four of them carrying a forward price. The next pages show where the pricing splits inside that single label.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE One Segment Label, Seven Platforms, Four Forward Prices Clinical-stage platforms with wholly owned pipelines cover the whole screen. 02 of 06 Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    One Segment Label Covers the Screen; The Pricing Splits Inside It

    This slide groups the seven companies by business segment and shows median EV/Revenue by group.

    All seven companies in this universe sit under one segment label — 100% of the set is grouped the same way. Grouping by segment still centers on a median EV / Revenue for CY2027E of 2.7x among the rated names, the same median we see across the broader set. Because the segment view doesn't separate the pricing on its own, the ranking inside the label is where the real differentiation shows up — so what matters next is company-level detail, not the group average.

    Everything on this page

    02 · MARKET MAP One Segment Label Covers the Screen; The Pricing Splits Inside It 7 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 CLINICAL-STAGE PLATFORM THERAPEUTICS WITH WHOLLY OWNED PIPELINES 7 cos median 2.7x Denali (DNLI) Benitec Biopharma (BNTC) Cellectis S.A. (CLLS) Caribou (CRBU) Bicycle (BCYC) Sangamo (SGMO) TScan Therapeutics (TCRX) Every company on this screen is grouped here, so the pricing question is settled inside the segment rather than between segments.

  6. 06
    02 · LANDSCAPE

    The Segment Label Only Takes You so Far on Price — the Ranking Takes You Further

    This slide ranks the approved companies within the segment by forward valuation.

    The segment label only takes a reader so far on price; the ranking on EV / Revenue for CY2027E takes it further, with rated names spread well above and below the 2.7x sector median. That spread is the practical starting point for comparing platforms against each other, rather than against the segment as a whole — so what a client should use is the ranking, not the label, to size up any one platform.

    Everything on this page

    02 · LANDSCAPE The Segment Label Only Takes You so Far on Price — the Ranking Takes You Further Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage platform therapeutics with wholly owned pipelines 7 100% 2.7x Denali Therapeutics Inc. (DNLI) · Benitec Biopharma Inc. (BNTC) · +5 more The whole screen, one label. Seven companies, 100% of the set, all running platforms with wholly owned pipelines and collaboration-led revenue. The middle of the segment sits at 2.7x forward revenue, with 4 of the 7 carrying a forward multiple. Because the label does not separate them, positioning is argued on candidate cadence, partner roster and retained downstream economics.

  7. 07
    SECTION 03

    03

    This divider introduces the valuation section built on forward revenue multiples.

    Forward revenue is the yardstick this market is read on: EV / Revenue for CY2027E applies across all seven companies, and four of them carry a rated multiple. The next pages walk through what separates those four.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS Forward Revenue Is the Yardstick This Market Is Read On EV / Revenue on CY2027E across the 7 companies on the page, 4 of them carrying a forward multiple. 03 of 06 Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Four Platforms Carry a Forward Price, and They Sit Far Apart

    This slide ranks the four rated companies by EV/Revenue for CY2027E against the sector median.

    Four platforms in this set carry a forward price, and they sit far apart: Denali Therapeutics Inc. (DNLI) holds the top at 18.3x EV / Revenue for CY2027E, while Cellectis S.A. (CLLS) sits at the bottom at 0.8x, against a sector median of 2.7x. We read the set on EV / Revenue because forward EBITDA is only meaningful for one of the seven names. A gap this wide between four rated companies means the segment average tells a client very little about any one of them — so the next question is what explains the top of the range versus the bottom.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Four Platforms Carry a Forward Price, and They Sit Far Apart EV / Revenue (CY2027E) · all 4 rated companies, sorted descending · sector median 2.7x · EV/Revenue is the lens because only 1 of 7 names carry a meaningful forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (4 of 7 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 18.3x CORE · median 2.7x DISCOUNT · median 0.8x Sector median 2.7x WHAT SEPARATES THE TWO ENDS The two ends of the range. Denali Therapeutics Inc. (DNLI) holds the top of the range at 18.3x forward revenue; Cellectis S.A. (CLLS) sits at the bottom at 0.8x. In this sector the premium end sits alongside evidence of platform reusability — repeat development candidates rather than one lead asset — and the forward lens has already credited the growth inside the estimate. Two names hold the middle. Benitec Biopharma Inc. (BNTC) and Caribou Biosciences, Inc. (CRBU) sit between the two ends, in the band the chart marks as Core. For companies in that band the argument is usually made on proof of mechanism and on how many partners have come back for a second target. Three of seven carry no price. Bicycle Therapeutics plc (BCYC), Sangamo Therapeutics, Inc. (SGMO) and TScan Therapeutics, Inc. (TCRX) appear on the page without a forward multiple. Their positioning is argued on the translational package, the partner roster and runway to the next readout rather than on a ranked multiple.

  9. 09
    03 · VALUATION DRIVERS

    Price Here Sits Alongside Candidate Cadence, Partner Behaviour and Runway

    This slide reads valuation alongside revenue-growth and margin cohorts among the rated names.

    We set price here alongside candidate cadence, partner behaviour and runway by splitting the rated names' EV / Revenue for CY2027E across revenue-growth and EBITDA-margin cohorts. These cuts are read as associations in the data we have, not as causation, and they're most useful where a company has both a rated multiple and the underlying estimates. For a client comparing platforms, growth and margin quality are two separate signals worth tracking together — so what matters is not picking one lever, but watching both.

    Everything on this page

    03 · VALUATION DRIVERS Price Here Sits Alongside Candidate Cadence, Partner Behaviour and Runway Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=0; slower n=0; higher-margin n=0; lower-margin n=0). Driver readings are NeuraCap views on the supplied data — association, not causation. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 Forward Growth Estimates in This Set Do Not Point the Same Way On the 4 companies carrying a forward growth estimate, the readings run from clearly negative to strongly positive. Caribou Biosciences, Inc. (CRBU) sits at 17% and TScan Therapeutics, Inc. (TCRX) at -1%, between the two ends of that group. A forward revenue lens reads those estimates directly, so an estimate that rests on a single contract behaves differently from one built on several partners. Revenue Here Is Upfronts, Milestones and Royalties What shows up as revenue in this set is collaboration economics: upfront payments, research funding, option exercises and the milestone and royalty stack. Two companies can report the same number with very different durability behind it. Repeat-partner rate and how much downstream economics were retained are what separate the two cases. Runway to the Next Catalyst Is Associated with the Terms on Offer Financing position is part of how this cohort transacts. A company funded through its next biomarker readout negotiates option-to-license terms from a different footing than one financing into the readout. This is an association visible in how deals in the sector are customarily structured, not a measured relationship in this screen. Foundational Intellectual Property Is Often In-Licensed, Not Owned In several modalities the underlying claims sit upstream with universities and institutes, carrying diligence obligations, field carve-outs and reversion rights. Composition-of-matter term and freedom to operate bound the realisable royalty window. These are standard gating items in diligence and they shape what a buyer will underwrite.

  10. 10
    03 · SITUATION MAP

    Value Here Is Concentrated at the Top of the Price Ranking, and the Margin Question Stays Open

    This slide maps rated companies on EV/Revenue against the sector median and against EBITDA margin.

    We cut this set on EV / Revenue against the 2.7x sector median, alongside EBITDA margin where a comparable reading exists. Value in this universe is concentrated at the top of the price ranking, and margin comparability stays limited across part of the set. These are observations on where each platform sits today, not recommendations — so what a client takes from this page is where the open questions are before committing capital.

    Everything on this page

    03 · SITUATION MAP Value Here Is Concentrated at the Top of the Price Ranking, and the Margin Question Stays Open Cut on EV / Revenue vs the sector median (2.7x) (rows) and EBITDA margin vs the covered median (n/a) (columns) · 4 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Priced up, with Margin Support Above-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Priced up, Investing Through the P&L Above-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Cash-Generative, Priced Below the Middle Below-median multiple · above-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date. Below the Middle on Both Lines Below-median multiple · below-median EBITDA margin 0 names No rated names sit in this cell as of the analysis date.

  11. 11
    03 · THE AGENDA

    The Capital Allocation Decisions Behind the Next Planning Cycle

    This slide frames the capital-allocation questions an owner or acquirer should resolve next.

    We frame this page as the questions an owner or acquirer should work through heading into the next planning cycle, drawn from the cohort data shown earlier in this report. These are our observations grounded in the pricing evidence, not recommendations to buy or sell any security. The agenda gives a client a working checklist — so what matters is using it to structure the next round of internal diligence.

    Everything on this page

    03 · THE AGENDA The Capital Allocation Decisions Behind the Next Planning Cycle NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 Fund the Second Development Candidate, or Concentrate Behind the Lead The top of the forward range in this set is held by a company with breadth across clinical-stage programs. Decide whether the next research dollar buys a second nominated candidate from the same platform or deepens the lead program's translational package. What changes the answer: A second development candidate nominated from the platform inside the planning year. Decide How Much Downstream Economics You Keep Option-to-license structures convert research into non-dilutive funding, but they move royalties and profit shares to the partner at the point where optionality is highest. Set a rule for which targets are partnered and which stay wholly owned before the next term sheet arrives. What changes the answer: A partner requesting broader territory or field rights on a nominated target. Match Runway to the Readout, Not to the Fiscal Calendar Financing position shapes the terms a company can hold out for in this sector. Work back from the next biomarker readout and size the cash to clear it, so negotiation is not happening while the overhang is visible to the counterparty. What changes the answer: A readout date slipping past the point the current cash covers. Test Freedom to Operate on In-Licensed Foundational Rights Where foundational claims sit upstream with a university or institute, diligence obligations, field carve-outs and reversion terms shape what a counterparty will underwrite. Resolve chain of title and composition-of-matter term before they become a gating item in someone else's diligence. What changes the answer: A diligence or reversion clause upstream becoming contested.

  12. 12
    SECTION 04

    04

    This divider introduces the precedent-transactions section covering nine recorded deals from 2019 to 2025.

    We move next to what buyers have actually paid for platform companies: nine recorded transactions from December 2019 to August 2025, with both strategic and sponsor buyers active. The following pages walk through that pricing evidence deal by deal.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS What Buyers Agreed to Pay for Platform Companies Nine recorded transactions from December 2019 to August 2025, with strategics and sponsors both active. 04 of 06 Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12

  13. 13
    04 · DEAL CASE STUDIES

    What Buyers Agreed to Pay for Discovery Platforms Since 2019

    This slide presents three of the recorded transactions as detailed case studies.

    Among the transactions with disclosed terms, whole-company strategic deals have run as high as $6.6B, where Johnson & Johnson acquired Momenta Pharmaceuticals, Inc. At the other end, Arlington Capital Partners' acquisition of IPA Europe B.V. reads, in our view, as a sponsor positioning around cash generation rather than clinical risk. These multiples sit on LTM financials at announcement, so they aren't directly comparable to the CY2027E public basis used elsewhere in this report — no spread between the two is claimed. For a client weighing strategic versus sponsor interest, these case studies show what each buyer type has actually been willing to underwrite.

    Everything on this page

    04 · DEAL CASE STUDIES What Buyers Agreed to Pay for Discovery Platforms Since 2019 3 of 12 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 42 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13 Feb-2022 $207M Dynamics Special Purpose Corp. Senti Biosciences took a route to public capital through Dynamics Special Purpose Corp. at $207M. EV / LTM revenue 82.3x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED A special purpose vehicle combining with a cell-therapy platform company suggests a financing route: the vehicle brings cash and a listing, the target brings the programs and the platform. For a company whose value sits in future development candidates rather than current revenue, this is a way to fund the next clinical steps without a partner taking downstream economics. HOW THE TARGET WAS VALUED The transaction was recorded at $207M enterprise value and 82.3x EV / Revenue, on value as recorded in the filing. That multiple sits well above the forward multiples the public companies on this screen carry, which is what happens when the revenue base is early collaboration income. Aug-2025 $85M AstraZeneca Treasury Limited AstraZeneca Treasury Limited completed the purchase of China operations at $85M. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED A large pharmaceutical buyer taking a regional operating base suggests a footprint and capability purchase rather than a pipeline purchase. The scale of the transaction points to an addition to existing infrastructure, which is the kind of asset a buyer with global development and regulatory capability can absorb quickly. HOW THE TARGET WAS VALUED Recorded at $85M enterprise value and completed in August 2025. Set against the whole-company transactions in this record, such as the $4.3B recorded for Biohaven Ltd., it sits at the small end of the range. Aug-2025 $12M Arlington Capital Partners Arlington Capital Partners completed the purchase of IPA Europe B.V. at $12M. EV / LTM revenue n/a EV / LTM EBITDA n/a WHY THE DEAL HAPPENED A financial sponsor buying a European discovery-services business fits the pattern of sponsor activity in this sector: it transacts where revenue is contracted and cash generation is legible, rather than where value rests on a binary clinical readout. The logic reads as building a services platform that sells into drug developers. HOW THE TARGET WAS VALUED The transaction is recorded at $12M enterprise value and completed in August 2025. It sits at the small end of this record, consistent with a services-edge asset rather than a clinical-stage pipeline.

  14. 14
    SECTION 05

    05

    This divider introduces the section on what current pricing means for a platform owner.

    We now turn to what this pricing means for a platform owner: candidate cadence, partner economics and runway are the levers management actually holds. The next page sets out our view on where to focus over the next two planning cycles.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What This Pricing Means for a Platform Owner Candidate cadence, partner economics and runway are the levers management actually holds. 05 of 06 Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14

  15. 15
    05 · STRATEGIC IMPLICATIONS

    Higher Multiples Sit with Revenue Quality and Runway — Build Both over the Next Two Planning Cycles

    This slide argues that higher multiples sit alongside revenue quality and runway, and recommends building both.

    Higher multiples in this set sit alongside revenue quality and runway, and in our view that's the pair worth building over the next two planning cycles. Pipeline breadth is associated with sitting nearer the top of the forward range, while dependence on a single lead program is associated with sitting lower. Collaboration terms and financing position are the levers management can act on between clinical readouts, rather than waiting on the market to reprice a single event. That's the operating agenda this report puts on the table for the next twelve months.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Higher Multiples Sit with Revenue Quality and Runway — Build Both over the Next Two Planning Cycles NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15 FOR OWNERS Breadth of the Clinical Pipeline Sits Alongside the Top of the Range In this set the top of the forward range is held by a company running multiple clinical-stage programs, while companies dependent on a single lead sit lower. The operating move is candidate cadence: how many development candidates the platform nominates a year, and how many partners come back for a second target. FOR BOARDS Revenue Quality Is Set in the Partnering Terms, Not in the Headline Total Announced collaboration totals bundle upfront, research funding, milestones and royalties. What the market reads on a forward revenue lens is the committed and recurring portion. Decide, target by target, how much of the milestone and royalty stack the company keeps before agreeing the next structure. FOR PARTNERING TEAMS Buyer Behaviour Splits by What the Buyer Already Owns In this record, large pharmaceutical and specialty buyers took whole companies with mechanisms they can scale, while a sponsor took a services asset at the smaller end. Pitch each counterparty group on what it is set up to absorb: development and regulatory reach on one side, contracted revenue on the other.

  16. 16
    SECTION 06

    06

    This divider introduces the appendix covering the full comparable universe, methodology and sources.

    This section carries the comparables detail behind every figure in the body, the valuation basis, and the sources for each underlying disclosure. Use it to trace any figure in this report back to where it came from.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16

  17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This slide lists the public comparables underlying the EV/Revenue analysis, grouped by valuation tier.

    This page lists the comparables behind the EV / Revenue for CY2027E analysis, with four companies carrying a rated multiple and three not rated for lack of an eligible figure. Shading marks names above versus below the 2.7x sector median, so a client can see at a glance where each company sits. Every company shown here ties back to public filings and consensus estimates as of September 28, 2026 — so what a client gets is a checkable foundation under the headline multiples used earlier.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.7x); amber marks below · 4 rated companies; 3 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 4 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥7.9x · median 18.3x · 1 companies Denali Therapeutics Inc. DNLI Clinical-stage platform therapeutics with wholly owned… $2.4B 18.3x n/a n/a n/a CORE — 0.9x–7.9x · median 2.7x · 2 companies Benitec Biopharma Inc. BNTC Clinical-stage platform therapeutics with wholly owned… $160M 4.4x n/a n/a n/a Caribou Biosciences, Inc. CRBU Clinical-stage platform therapeutics with wholly owned… $29M 1.0x 17% n/a n/a DISCOUNT — <0.9x · median 0.8x · 1 companies Cellectis S.A. CLLS Clinical-stage platform therapeutics with wholly owned… $72M 0.8x 72% n/a n/a

  18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide lists precedent transactions with disclosed terms, newest first (part one).

    This page lists precedent transactions with disclosed terms, newest first, with multiples read on LTM financials at announcement. These deal multiples aren't directly comparable to the CY2027E public basis used elsewhere in this report, and no spread between the two is claimed. For a client benchmarking a potential transaction, this list is the closest thing to a market clearing price this sector has produced.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 12 transactions with disclosed terms in this tier (45 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 42 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Aug-2025 AstraZeneca Treasury Limited → China operations $85M n/a n/a AstraZeneca Treasury Limited acquired China operations in August 2025 at $85M enterprise value, recorded as completed. A purchase of this size reads as regional footprint rather than a whole-platform acquisition. Aug-2025 Arlington Capital Partners → IPA Europe B.V. $12M n/a n/a Arlington Capital Partners completed the purchase of IPA Europe B.V. in August 2025 at $12M enterprise value. Financial sponsors in this sector are most active where cash generation is legible, which is the discovery-services and platform-licensing edge. Mar-2024 n/a → Biohaven Ltd. $4.3B n/a n/a Biohaven Ltd. was recorded at $4.3B enterprise value in March 2024, with the counterparty listed as n/a and the status announced. Value is shown as recorded in the filing. Feb-2022 Dynamics Special Purpose Corp. → Senti Biosciences, Inc. $207M 82.3x n/a Dynamics Special Purpose Corp. and Senti Biosciences, Inc. were announced in February 2022 at $207M enterprise value and 82.3x EV / Revenue. The revenue base behind that multiple is early collaboration income rather than product sales. Feb-2022 Novo Nordisk A/S → Dicerna Pharmaceuticals n/a 14.2x n/a Novo Nordisk A/S and Dicerna Pharmaceuticals was announced in February 2022 at 14.2x EV / Revenue. A buyer of this type already carries the development, regulatory and commercial infrastructure a platform company lacks. Apr-2021 Roivant Sciences Ltd. → Silicon Therapeutics LLC $5.0B 0.7x 8.8x Roivant Sciences Ltd. and Silicon Therapeutics LLC was recorded at $5.0B enterprise value, 0.7x EV / Revenue and 8.8x EV / EBITDA in April 2021, with the status recorded as terminated. Announced terms are not realised terms. Nov-2020 PerkinElmer, Inc. → Horizon Discovery Group plc n/a 5.2x n/a PerkinElmer, Inc. and Horizon Discovery Group plc was announced in November 2020 at 5.2x EV / Revenue. Buyers of research tools are pricing a revenue stream they can apply across an existing customer base. Aug-2020 Johnson & Johnson → Momenta Pharmaceuticals, Inc. $6.6B 0.7x 8.8x Johnson & Johnson completed the acquisition of Momenta Pharmaceuticals, Inc. in August 2020 at $6.6B enterprise value, 0.7x EV / Revenue and 8.8x EV / EBITDA. Value is shown as recorded in the filing. Dec-2019 Sanofi S.A. → Synthorx, Inc. n/a 1.6x n/a Sanofi S.A. and Synthorx, Inc. was announced in December 2019 at 1.6x EV / Revenue. The fit reads as a specialist biology capability moving to a buyer with late-stage development reach.

  19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This slide continues the list of precedent transactions with disclosed terms, newest first.

    This page continues the same list of disclosed-term transactions, still ordered newest first and read on LTM financials at announcement. Taken together with the prior page, it's the fullest picture of what buyers have agreed to pay across this sector since 2019. A client sizing a partnership or a sale can use this record as a reference point, alongside the public multiples shown earlier in this report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 12 transactions with disclosed terms in this tier (45 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 42 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 33 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Dec-2019 Merck & Co., Inc. → ArQule, Inc. n/a 1.4x n/a Aug-2019 Tonix Pharmaceuticals Holding Corp. → TRImaran Pharma, Inc. $0M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Feb-2019 Merck (NYSE: MRK) → Immune Design Corp. n/a 0.7x n/a Value shown as recorded in the filing; deal value unit unresolved.

  20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This slide sets out the report's sources, assumptions and data-quality treatment.

    This page sets out the basis for every figure in this report: the valuation convention used, which comparables and transactions were excluded and why, and where each underlying disclosure sits in SEC filings, consensus estimates or market prices as of September 28, 2026. Knowing that basis lets a client see exactly what stands behind any multiple or deal figure quoted earlier. That traceability is what makes the pricing evidence in this report usable in a live negotiation, not just a reference point.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (4 of 7 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Therapeutic Discovery Platforms and it clears the coverage gate with 7 of 7 companies (100%). No secondary cross-check clears its own gate. A revenue lens is used rather than a profit multiple because the cohort's median forward revenue growth is 45%, and a set priced on growth is read on revenue. DATA QUALITY & EXCLUSIONS 42 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 256 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (255) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  21. 21

    One Segment Label Here, Seven Platforms, and Four Forward Prices That Sit Far Apart.

    This closing slide restates that one segment label covers seven platforms priced far apart.

    One segment label covers seven platforms here, and four of them carry a forward price that sits far apart — from 18.3x down to 0.8x against a 2.7x median. That gap is why a segment-level average won't tell a client what any one platform is worth. We'd size the next partnering, financing or portfolio decision off the company-level pricing shown in this report, not off the label.

    Everything on this page

    One Segment Label Here, Seven Platforms, and Four Forward Prices That Sit Far Apart. NeuraCap AI — Therapeutic Discovery Platforms Coverage September 2026 · Prepared by NeuraCap AI · Confidential Therapeutic Discovery Platforms Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21

Sources and methodology

This report covers Therapeutic Discovery Platforms (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Therapeutic Discovery Platforms) with market data and consensus estimates as of September 28, 2026. The company universe is the 7 listed companies whose core business is Therapeutic Discovery Platforms according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Bicycle Therapeutics plc (BCYC), Benitec Biopharma Inc. (BNTC), Cellectis S.A. (CLLS), Caribou Biosciences, Inc. (CRBU), Denali Therapeutics Inc. (DNLI), Sangamo Therapeutics, Inc. (SGMO), TScan Therapeutics, Inc. (TCRX). The market map groups them by business vertical — Clinical-stage platform therapeutics with wholly owned pipelines: 7 companies (DNLI, BNTC, CLLS, CRBU, BCYC, SGMO, TCRX). 4 of the 7 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Therapeutic Discovery Platforms (Health Care › Pharmaceuticals, Biotechnology and Life Sciences › Therapeutic Discovery Platforms) with market data and consensus estimates as of September 28, 2026. The company universe is the 7 listed companies whose core business is Therapeutic Discovery Platforms according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Bicycle Therapeutics plc (BCYC), Benitec Biopharma Inc. (BNTC), Cellectis S.A. (CLLS), Caribou Biosciences, Inc. (CRBU), Denali Therapeutics Inc. (DNLI), Sangamo Therapeutics, Inc. (SGMO), TScan Therapeutics, Inc. (TCRX). The market map groups them by business vertical — Clinical-stage platform therapeutics with wholly owned pipelines: 7 companies (DNLI, BNTC, CLLS, CRBU, BCYC, SGMO, TCRX). 4 of the 7 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

42 records failed a validation gate and never feed a statistic in this report (1 excluded from universe; 33 excluded from aggregate; 8 quarantined). Each exclusion, with its reason: NKTR — The ticker NKTR carries a preferred, warrant or unit suffix and the security name gives no sign of an operating company (effect: excluded from universe) · BCYC — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BCYC — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BCYC — Implied EBITDA margin -615.9% outside the plausible band [-100%, 80%] (effect: quarantined) · BCYC — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · BCYC — Implied EBITDA margin -1871.3% outside the plausible band [-100%, 80%] (effect: quarantined) · BCYC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · BNTC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLLS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CRBU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CRBU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CRBU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CRBU — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DNLI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DNLI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DNLI — Implied EBITDA margin -1334.8% outside the plausible band [-100%, 80%] (effect: quarantined) · DNLI — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · DNLI — Implied EBITDA margin -350.2% outside the plausible band [-100%, 80%] (effect: quarantined) · DNLI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DNLI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DNLI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · DNLI — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (4 of 7 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Therapeutic Discovery Platforms and it clears the coverage gate with 7 of 7 companies (100%). No secondary cross-check clears its own gate. A revenue lens is used rather than a profit multiple because the cohort's median forward revenue growth is 45%, and a set priced on growth is read on revenue. The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 1 of 7 companies; EV / rEVenue: 7 of 7 companies; P/E: 0 of 7 companies. 5 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥7.9x, Core 0.9x–7.9x, Discount <0.9x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 2.7x = median(ev_revenue CY2027E) (4 rated companies) · 18.3x = median(ev_revenue CY2027E) within Premium tier (n=1) · 2.7x = median(ev_revenue CY2027E) within Core tier (n=2) · 0.8x = median(ev_revenue CY2027E) within Discount tier (n=1)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Therapeutic Discovery Platforms recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 45 transactions were recorded for this industry; 12 are shown. 33 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 25 × deal value unit unresolved; 14 × no evidence record; 2 × duplicate precedent id; 1 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 260 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Therapeutic Discovery Platforms?

Company valuation reports run the same method against a single business — public or private.